A detailed history of New Edge Advisors, LLC transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 300 shares of ABCL stock, worth $876. This represents 0.0% of its overall portfolio holdings.

Number of Shares
300
Previous 600 50.0%
Holding current value
$876
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.39 - $3.49 $717 - $1,047
-300 Reduced 50.0%
300 $0
Q1 2024

May 14, 2024

BUY
$4.29 - $5.97 $1,287 - $1,791
300 Added 100.0%
600 $2,000
Q1 2023

May 12, 2023

SELL
$7.31 - $11.18 $3,070 - $4,695
-420 Reduced 58.33%
300 $2,000
Q4 2022

Feb 14, 2023

BUY
$9.48 - $14.52 $6,825 - $10,454
720 New
720 $7,000

Others Institutions Holding ABCL

About AbCellera Biologics Inc.


  • Ticker ABCL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 285,139,008
  • Market Cap $833M
  • Description
  • AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...
More about ABCL
Track This Portfolio

Track New Edge Advisors, LLC Portfolio

Follow New Edge Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of New Edge Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on New Edge Advisors, LLC with notifications on news.